Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (394)	1/1/1999 6:18:00 AM
From: Mike McFarland	Read Replies (4) \| Respond to of 4474

Administration of rapamycin resulted in 200-fold induction of plasma Epo Does this (ARGENT?) sound like something that Avigen might be interested in? biz.yahoo.com ''The broadest claim covers AAV vectors carrying the EPO gene -- regardless of the method used to make the vector, where the vector is administered, or even what disease is being treated.'' Any thoughts from biotechies much appreciated, I missed out on most of the move in Avigen, I'd hate to miss out on a move in Ariad. --Mike